MGNX MacroGenics Inc.

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:

  • Stifel 2023 Targeted Oncology Days (Virtual). Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in a formal presentation on Wednesday, April 26, 2023, at 2:00 pm ET. MacroGenics’ management will also participate in one-on-one meetings. 
  • H.C. Wainwright BioConnect Investor Conference at NASDAQ (New York). Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 2, 2023, at 1:00 pm ET. MacroGenics’ management will also participate in one-on-one meetings.
  • The JMP Securities Life Sciences Conference (New York). Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Monday, May 15, 2023, at 9:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at /events.cfm.  The Company will maintain archived replays of these webcasts on its website for 30 days.   

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###



CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,   
EN
24/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MacroGenics Inc.

 PRESS RELEASE

MacroGenics Provides Update on Corporate Progress and 2023 Financial R...

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADCPreclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, to be presented in posters at AACRConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on di...

Macrogenics Inc: 3 directors

Three Directors at Macrogenics Inc sold after exercising options/sold 81,159 shares at between 19.765USD and 20.500USD. The significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all t...

 PRESS RELEASE

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2024: TD Cowen’s 44th Annual Health Care Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a Prostate Ca...

 PRESS RELEASE

MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Co...

MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March ...

 PRESS RELEASE

MacroGenics to Participate in Upcoming Investor Conference

MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference (New York).  MacroGenics’ President and CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch